JP2016529284A - ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 - Google Patents

ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 Download PDF

Info

Publication number
JP2016529284A
JP2016529284A JP2016537829A JP2016537829A JP2016529284A JP 2016529284 A JP2016529284 A JP 2016529284A JP 2016537829 A JP2016537829 A JP 2016537829A JP 2016537829 A JP2016537829 A JP 2016537829A JP 2016529284 A JP2016529284 A JP 2016529284A
Authority
JP
Japan
Prior art keywords
formulation
olaparib
lipid
parp
parp inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016537829A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016529284A5 (enExample
Inventor
タングテューリ，シャファリカ
スリデゥハ，スリニヴァス
Original Assignee
ノースイースタン ユニバーシティ
ノースイースタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースイースタン ユニバーシティ, ノースイースタン ユニバーシティ filed Critical ノースイースタン ユニバーシティ
Publication of JP2016529284A publication Critical patent/JP2016529284A/ja
Publication of JP2016529284A5 publication Critical patent/JP2016529284A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016537829A 2013-08-27 2014-08-27 ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法 Pending JP2016529284A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361870258P 2013-08-27 2013-08-27
US61/870,258 2013-08-27
PCT/US2014/053006 WO2015031536A1 (en) 2013-08-27 2014-08-27 Nanoparticle drug delivery system and method of treating cancer and neurotrauma

Publications (2)

Publication Number Publication Date
JP2016529284A true JP2016529284A (ja) 2016-09-23
JP2016529284A5 JP2016529284A5 (enExample) 2017-10-05

Family

ID=52587308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016537829A Pending JP2016529284A (ja) 2013-08-27 2014-08-27 ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法

Country Status (4)

Country Link
US (1) US10111871B2 (enExample)
EP (1) EP3038600B1 (enExample)
JP (1) JP2016529284A (enExample)
WO (1) WO2015031536A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536708A (ja) * 2019-06-12 2022-08-18 リーベン アイピー ホールディングカンパニー リミテッド ライアビリティ カンパニー がん患者の予後を改善する方法および組成物

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
PT3313443T (pt) * 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
HK1257216A1 (zh) 2015-08-20 2019-10-18 益普生生物制药有限公司 使用脂质体伊立替康和parp抑制剂用於癌症治疗的组合疗法
BR112018002941B1 (pt) 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
BR112018006922B1 (pt) 2015-10-16 2023-11-21 Ipsen Biopharm Ltd Composições de irinotecano lipossômico estabilizado para armazenamento
WO2017136330A1 (en) * 2016-02-01 2017-08-10 Abbvie Inc. Extended release formulations of veliparib for the treatment of cancer
GB201608885D0 (en) * 2016-05-20 2016-07-06 Univ Birmingham Treatment
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
CN108201536A (zh) 2016-12-16 2018-06-26 中国科学院上海药物研究所 一种奥拉帕尼口服缓控释药物组合物及其用途
CN108201535A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种维利帕尼缓控释药物组合物及其用途
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
US11737977B2 (en) * 2017-04-12 2023-08-29 Beijing Inno Medicine Co., Ltd. Cerasome delivery system for targeting activated CD44 molecule, preparation method and use thereof
US20210030680A1 (en) * 2018-04-13 2021-02-04 The Board Of Regents Of University Of Texas System Nanoparticle compositions and methods of use of parp inhibitor for treatment of cancer
KR102017115B1 (ko) * 2018-05-15 2019-09-02 충남대학교산학협력단 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물
US11648211B2 (en) * 2019-09-23 2023-05-16 Northeastern University Nanoencapsulated combination drug formulations
CN111187416A (zh) * 2020-01-17 2020-05-22 广州古泉生物科技有限公司 一种壳聚糖-g-聚ε-己内酯衍生物载药纳米胶束的制备方法和应用
WO2022115207A1 (en) * 2020-11-25 2022-06-02 Trustees Of Dartmouth College Method for attenuating neuroinflammation
PL438742A1 (pl) * 2021-08-14 2023-02-20 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック，インコーポレイテッド ルカパリブ粒子およびその使用
US20250223571A1 (en) 2022-03-30 2025-07-10 Bioneedle Drug Delivery B.V. A process for storing biologically active constructs in a biodegradable material
CN116297044A (zh) * 2022-12-07 2023-06-23 浙江萃泽医药科技有限公司 一种糠酸莫米松鼻喷雾剂中微晶纤维素粒径的测试方法
WO2025024581A1 (en) * 2023-07-24 2025-01-30 University Of Maryland, College Park Parp-inhibitor nanoparticles and methods thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001026544A (ja) * 1999-05-11 2001-01-30 Sankyo Co Ltd 脂溶性抗腫瘍薬のリポソーム製剤
KR20090013848A (ko) * 2007-08-03 2009-02-06 한국화학연구원 안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법
WO2009096487A1 (ja) * 2008-01-30 2009-08-06 The University Of Tokushima オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
US20100104629A1 (en) * 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
WO2012031205A2 (en) * 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058940C (en) 1989-06-23 2000-05-09 Helen Loughrey Targeted liposomes and methods for liposome-protein coupling
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NL9000207A (enExample) 1990-01-29 1991-08-16 Duphar Int Res
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US7037520B2 (en) * 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
AU2006204699B2 (en) * 2005-01-13 2012-04-26 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
US20090220587A1 (en) 2005-02-01 2009-09-03 United State Army Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
BRPI0717800A2 (pt) * 2006-10-06 2014-09-09 Politechnic Inst Univ New York COMPOSIÇÃO DE LIPOSSOMAS SENSÍVEIS AO pH
EP2118127A4 (en) 2007-01-31 2010-12-01 Affymax Inc NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
US20100129456A1 (en) * 2007-05-14 2010-05-27 Ltt Bio-Pharma Co., Ltd. Sustained-release nanoparticle containing low-molecular-weight drug with negatively charged group
US20110233079A1 (en) * 2009-06-30 2011-09-29 Macinnes Susan E Medical Kit, Packaging System, Instruction Insert, and Associated Methods
WO2009129387A2 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
US20110123451A1 (en) 2009-11-21 2011-05-26 Max Kullberg Method for Cell Delivery Using Targeted Liposomes Associated with a Hemolysin
MX340319B (es) 2010-02-08 2016-07-06 Medivation Technologies Inc Procesos para sintetizar derivados de dihidropiridoftalazinona.
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001026544A (ja) * 1999-05-11 2001-01-30 Sankyo Co Ltd 脂溶性抗腫瘍薬のリポソーム製剤
KR20090013848A (ko) * 2007-08-03 2009-02-06 한국화학연구원 안트라사이클라인계 항암약물 봉입용 리포솜 및 이의제조방법
WO2009096487A1 (ja) * 2008-01-30 2009-08-06 The University Of Tokushima オキサリプラチンリポソーム製剤からなる抗腫瘍効果増強剤及び当該リポソーム製剤を含有する抗腫瘍剤
US20100104629A1 (en) * 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
WO2012031205A2 (en) * 2010-09-03 2012-03-08 The Brigham And Women's Hospital, Inc. Lipid-polymer hybrid particles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLANCO, MD., ET. AL., "CHAPTER 9: TARGETED NANOPARRICLES FOR CANCER THERAPY", RECENT ADVANCES IN NOVEL DRUG CARRIER SYSTEM, JPN6018022118, ISSN: 0003967431 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022536708A (ja) * 2019-06-12 2022-08-18 リーベン アイピー ホールディングカンパニー リミテッド ライアビリティ カンパニー がん患者の予後を改善する方法および組成物

Also Published As

Publication number Publication date
EP3038600A4 (en) 2017-03-01
US20160206615A1 (en) 2016-07-21
EP3038600A1 (en) 2016-07-06
WO2015031536A1 (en) 2015-03-05
EP3038600B1 (en) 2020-06-03
US10111871B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
US10111871B2 (en) Nanoparticle drug delivery system and method of treating cancer and neurotrauma
Iturrioz-Rodríguez et al. Current advances in temozolomide encapsulation for the enhancement of glioblastoma treatment
Wang et al. Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein
Zhang et al. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy
Zhang et al. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy
Lu et al. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer
US11648211B2 (en) Nanoencapsulated combination drug formulations
CN117159470A (zh) 脂质体包封的亲和性药物
JP2010180210A (ja) 併用薬剤を送達するための組成物
Al‐Ahmady et al. Triggered doxorubicin release in solid tumors from thermosensitive liposome‐peptide hybrids: Critical parameters and therapeutic efficacy
Han et al. Therapeutic efficacy of doxorubicin delivery by a CO2 generating liposomal platform in breast carcinoma
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
US20230172856A1 (en) Liposome formulations for treatment of cancers and drug resistance of cancers
Kumar et al. Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma
WO2008038291A1 (en) Combination of liposomal anti-cancer drugs and lysosome/endosome ph increasing agents for therapy
Orthmann et al. Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes
Gupta et al. Lipid-based nanocarriers in the treatment of glioblastoma multiforme (GBM): challenges and opportunities
Behl et al. Nano-based drug delivery of anticancer chemotherapeutic drugs targeting breast cancer
US20130164379A1 (en) Nanoparticle micelle coated compositions
WO2018019284A1 (en) Compounds for enhancing bax/bcl-2 expression and activity and therapeutic use thereof
Gutierrez et al. Photochemical internalization with verteporfin-liposomes enhances oxaliplatin retention and efficacy in models of pancreatic cancer
CN106061470A (zh) 含有多种物质的聚合物纳米粒子及其方法
Wang et al. ang,.(2025)
US20220118116A1 (en) Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance
Baldwin¹ et al. for Treatment of Ewing Sarcoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190205